1 / 4

Global NASH Drugs Market 2016 Edition Report

MarketReportsOnline.com adds "Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2016-2025)" report to its research store.<br><br>Non-alcoholic steatohepatitis or NASH is a common term for “silent” liver disease. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to work properly.<br><br>Complete report on Non-Alcoholic Steatohepatitis (NASH) Drugs Market spread across 68 pages providing 4 company profiles and 9 tables and 34 charts is now available at http://www.marketreportsonline.com/518870.html.

calebjackson
Download Presentation

Global NASH Drugs Market 2016 Edition Report

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2016-2025) Order this report by calling +1 888 391 5441 or Send an email to sales@marketreportsonline.com with your contact details and questions if any. • Published: November 2016 • Pages: 68 • Price: US$ 800 (Single User License)

  2. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2016-2025) Non-alcoholic steatohepatitis or NASH is a common term for “silent” liver disease. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to work properly. There are two main types of fatty liver disease: alcohol-related fatty liver disease and non-alcoholic fatty liver disease (NAFLD). NASH is also associated with lysosomal acid lipase deficiency. Patients with only steatosis but no fibrosis can progress to NASH. NASH itself can remain asymptomatic for years, or it can progress to cirrhosis and hepatocellular carcinoma. Risk factors such as insulin resistance related to obesity are central to the pathogenesis of NASH. Methods to diagnose NASH include MRI, CT or X-rays, however, only liver biopsy is reliable. There are no approved NASH drugs available in the market, but they are expected to enter the market by 2020. The potential NASH drug candidate include Elafirbranor, OCA, CVC and Aramchol. Currently, off-label drugs and therapies are employed to counter the progression of NASH. The global NASH drugs market is expected to experience robust growth post the launch of NASH therapeutic drugs, primarily due to increasing patient base, rise in obese population, increasing number of people suffering from type-2 diabetes coupled with increasing healthcare expenditure. However, the market growth is hindered by the unavailability of effective biomarkers, high cost of drugs and undefined pathogenesis.

  3. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2016-2025) The report “Global NASH Drugs Market: Industry Analysis & Outlook (2016-2020)” analyzes the development of this market, with focus on the US and Europe markets. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Genfit SA, Intercept Pharmaceuticals, Inc., Tobira Therapeutics Inc. and Galmed Pharmaceuticals Ltd. are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global NASH market along with the study of the regional markets. Key Topics Covered: 1. Introduction 2. Global NASH Market 3. Global NASH Therapeutics Market 4. Regional NASH Market 5. Market Dynamics 6. Competitive Landscape 7. Company Profiles Purchase a copy of this “Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2016-2025)” research report at USD 800 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=518870. Ultrasound

  4. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2016-2025) Global Thalassemia Market Report: 2016 Edition About Us: MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports. Contact Us: RiteshTiwari 2nd Floor, Metropole, Next to Inox Theatre, Bund Garden Road, Pune, Maharashtra, India Tel: + 1 888 391 5441 E-mail: sales@marketreportsonline.com http://www.marketreportsonline.com/

More Related